Insider Transactions in Q1 2025 at Acadia Pharmaceuticals Inc (ACAD)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,095
-4.89%
|
$18,615
$17.05 P/Share
|
|
Mar 26
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,171
-5.28%
|
$53,907
$17.05 P/Share
|
|
Mar 25
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,142
+8.74%
|
-
|
|
Mar 25
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,178
+9.33%
|
-
|
|
Mar 05
2025
|
Elizabeth A. Garofalo |
SELL
Open market or private sale
|
Direct |
4,919
-21.85%
|
$88,542
$18.23 P/Share
|
|
Feb 24
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
773
-1.41%
|
$14,687
$19.96 P/Share
|
|
Feb 24
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
475
-2.29%
|
$9,025
$19.96 P/Share
|
|
Feb 23
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,353
+2.42%
|
-
|
|
Feb 23
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
840
+3.9%
|
-
|